The U.S. life-sciences market has slowed considerably since its heyday in the wake of the Covid-19 pandemic, creating a demand gap in major lab markets with robust construction pipelines and a weaker leasing market.
The U.S. life-sciences market has slowed considerably since its heyday in the wake of the Covid-19 pandemic, creating a demand gap in major lab markets with robust construction pipelines and a weaker leasing market.
